{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:36:32Z","timestamp":1791329792014,"version":"4.3.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.beha.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T04:16:34Z","timestamp":1470888994000},"page":"79-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers"],"prefix":"10.1016","volume":"29","author":[{"given":"Carlos I.","family":"Amaya-Chanaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Z.","family":"Rassenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9617","key":"10.1016\/j.beha.2016.08.005_bib1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(08)60456-0","article-title":"Chronic lymphocytic leukaemia","volume":"371","author":"Dighiero","year":"2008","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrclinonc.2010.167","article-title":"Prognostic factors in chronic lymphocytic leukemia-what do we need to know?","volume":"8","author":"Cramer","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beha.2016.08.005_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2016.08.005_bib5","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/sj.leu.2404802","article-title":"The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia","volume":"21","author":"Kay","year":"2007","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.beha.2016.08.005_bib6","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1182\/blood-2010-06-288274","article-title":"Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters","volume":"116","author":"Letestu","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2016.08.005_bib7","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2016.08.005_bib8","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2016.08.005_bib9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia","volume":"351","author":"Rassenti","year":"2004","journal-title":"N Engl J Med"},{"issue":"1-2","key":"10.1016\/j.beha.2016.08.005_bib10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/10428190109097682","article-title":"CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia","volume":"42","author":"D'Arena","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.beha.2016.08.005_bib11","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood-2005-12-051458","article-title":"Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia","volume":"109","author":"Wierda","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11899-011-0110-1","article-title":"Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?","volume":"7","author":"Sellner","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"10.1016\/j.beha.2016.08.005_bib14","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3109\/10428194.2014.898760","article-title":"NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment","volume":"55","author":"Chiaretti","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.beha.2016.08.005_bib15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clml.2013.12.016","article-title":"Novel prognostic gene mutations identified in chronic lymphocytic leukemia and their impact on clinical practice","volume":"14","author":"Campregher","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"10.1016\/j.beha.2016.08.005_bib16","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood.V89.7.2516","article-title":"11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis","volume":"89","author":"Dohner","year":"1997","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2016.08.005_bib17","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2016.08.005_bib18","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2005.04.177","article-title":"Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data","volume":"23","author":"Hoang","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2016.08.005_bib20","doi-asserted-by":"crossref","first-page":"e48485","DOI":"10.1371\/journal.pone.0048485","article-title":"Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14","volume":"7","author":"Rodriguez","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.beha.2016.08.005_bib21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2141.2003.04265.x","article-title":"Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia","volume":"121","author":"Dewald","year":"2003","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.beha.2016.08.005_bib22","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1200\/JCO.2006.06.1077","article-title":"Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia","volume":"24","author":"Shanafelt","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2016.08.005_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3324\/haematol.13862","article-title":"A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia","volume":"94","author":"Hernandez","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2011.049270","article-title":"ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression","volume":"97","author":"Guarini","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3324\/haematol.2011.057109","article-title":"ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter","volume":"97","author":"Rossi","year":"2012","journal-title":"Haematologica"},{"issue":"9747","key":"10.1016\/j.beha.2016.08.005_bib26","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.beha.2016.08.005_bib27","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1046\/j.1365-2141.1996.d01-1478.x","article-title":"Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients","volume":"92","author":"Matutes","year":"1996","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/leu.2008.274","article-title":"The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype","volume":"23","author":"Dicker","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2016.08.005_bib29","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","article-title":"Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up","volume":"112","author":"Zenz","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2016.08.005_bib30","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","article-title":"p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias","volume":"85","author":"Dohner","year":"1995","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2016.08.005_bib31","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3324\/haematol.2010.025338","article-title":"Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation","volume":"95","author":"Oscier","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2016.08.005_bib32","first-page":"580","article-title":"Is T-cell CLL a disease entity?","volume":"94","author":"Catovsky","year":"1996","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.beha.2016.08.005_bib33","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.4161\/cc.7.24.7245","article-title":"Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway","volume":"7","author":"Zenz","year":"2008","journal-title":"Cell Cycle"},{"issue":"34","key":"10.1016\/j.beha.2016.08.005_bib34","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1200\/JCO.2007.11.2649","article-title":"Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion","volume":"25","author":"Austen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2016.08.005_bib35","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3324\/haematol.10720","article-title":"Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival","volume":"92","author":"Stilgenbauer","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2016.08.005_bib36","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"Krober","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2016.08.005_bib37","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","article-title":"Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors","volume":"100","author":"Oscier","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2016.08.005_bib38","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1046\/j.1365-2141.2001.03149.x","article-title":"Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia","volume":"115","author":"Jelinek","year":"2001","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2016.08.005_bib39","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1080\/10428190600947727","article-title":"CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia","volume":"47","author":"Hayat","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.beha.2016.08.005_bib40","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1182\/blood-2007-12-130229","article-title":"Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection","volume":"111","author":"Ghia","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2016.08.005_bib41","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood.V99.6.2262","article-title":"Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia","volume":"99","author":"Tobin","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2016.08.005_bib42","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1182\/blood-2002-11-3485","article-title":"Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope","volume":"101","author":"Tobin","year":"2003","journal-title":"Blood"},{"issue":"9403","key":"10.1016\/j.beha.2016.08.005_bib43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(03)15260-9","article-title":"ZAP-70 expression and prognosis in chronic lymphocytic leukaemia","volume":"363","author":"Orchard","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beha.2016.08.005_bib44","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-05-429282","article-title":"The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial","volume":"121","author":"Oscier","year":"2013","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2016.08.005_bib45","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2402339","article-title":"CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia","volume":"16","author":"Durig","year":"2002","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2016.08.005_bib47","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood.V98.9.2633","article-title":"Clinical significance of CD38 expression in chronic lymphocytic leukemia","volume":"98","author":"Del Poeta","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2016.08.005_bib48","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia","volume":"112","author":"Rassenti","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2016.08.005_bib49","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2002-06-1801","article-title":"The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression","volume":"101","author":"Ghia","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib50","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V98.1.181","article-title":"CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia","volume":"98","author":"Ibrahim","year":"2001","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2016.08.005_bib51","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2002-06-1683","article-title":"Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia","volume":"100","author":"Chen","year":"2002","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2016.08.005_bib52","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJMoa023143","article-title":"ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia","volume":"348","author":"Crespo","year":"2003","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2016.08.005_bib53","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/sj.leu.2403147","article-title":"ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia","volume":"17","author":"Durig","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2016.08.005_bib54","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.2005.03.7184","article-title":"Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia","volume":"24","author":"Krober","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2016.08.005_bib55","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.sla.0000133125.85489.07","article-title":"Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas","volume":"240","author":"Brennan","year":"2004","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.beha.2016.08.005_bib56","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2016.08.005_bib57","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.beha.2016.08.005_bib58","series-title":"Applied logistic regression","author":"Hosmer","year":"2000"},{"issue":"2","key":"10.1016\/j.beha.2016.08.005_bib59","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/bjh.13032","article-title":"Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases","volume":"167","author":"Gentile","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.beha.2016.08.005_bib60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hon.959","article-title":"Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia","volume":"29","author":"Bulian","year":"2011","journal-title":"Hematol Oncol"},{"issue":"7354","key":"10.1016\/j.beha.2016.08.005_bib61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.beha.2016.08.005_bib62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/leu.2014.196","article-title":"Recurrent mutations refine prognosis in chronic lymphocytic leukemia","volume":"29","author":"Baliakas","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2016.08.005_bib63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12079-015-0271-0","article-title":"The NOTCH signaling pathway in normal and malignant blood cell production","volume":"9","author":"Suresh","year":"2015","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.beha.2016.08.005_bib64","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/1471-2407-13-274","article-title":"NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients","volume":"13","author":"Willander","year":"2013","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.beha.2016.08.005_bib65","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.beha.2016.08.005_bib66","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2016.08.005_bib67","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2016.08.005_bib68","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2016.08.005_bib69","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.23993","article-title":"Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia","volume":"115","author":"Tsimberidou","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beha.2016.08.005_bib70","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nri3190","article-title":"Integration of B cell responses through Toll-like receptors and antigen receptors","volume":"12","author":"Rawlings","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"24","key":"10.1016\/j.beha.2016.08.005_bib71","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2013-12-543306","article-title":"Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome","volume":"123","author":"Martinez-Trillos","year":"2014","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261630007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261630007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T02:29:14Z","timestamp":1601000954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169261630007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S152169261630007X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}